MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

biologic eligibility

  • Home
  • biologic eligibility
Trajectory of Exacerbations in Biologic-Eligible Severe Asthma: Insights from UK Nationwide Data
Posted inAllergy & Immunology news Respiratory

Trajectory of Exacerbations in Biologic-Eligible Severe Asthma: Insights from UK Nationwide Data

Posted by By MedXY 10/11/2026
A large UK study reveals that over two-thirds of biologic-eligible severe asthma patients improve without biologic therapy, identifying distinct exacerbation trajectories linked to blood eosinophil levels and disease phenotype.
Read More
  • Prognostic Significance of Telomere Length in Chronic Lymphocytic Leukemia Under Venetoclax-Based First-Line Therapy
  • High Efficacy and Safety of Glofitamab Plus Polatuzumab-R-CHP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Multicenter Study
  • Efficacy and Safety of Ziftomenib Combined with Venetoclax and Azacitidine in Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
  • Optimizing ICU Pharmacist Workload: Impact on Patient Mortality and Medication Management
  • Trajectory of Exacerbations in Biologic-Eligible Severe Asthma: Insights from UK Nationwide Data
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top